

Accepted Manuscript

Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease

Dilan Athauda, Thomas Foltynie

PII: S0028-3908(17)30440-9

DOI: [10.1016/j.neuropharm.2017.09.023](https://doi.org/10.1016/j.neuropharm.2017.09.023)


Reference: NP 6867

To appear in: *Neuropharmacology*

Received Date: 22 August 2017

Revised Date: 12 September 2017

Accepted Date: 15 September 2017



Please cite this article as: Athauda, D., Foltynie, T., Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease, *Neuropharmacology* (2017), doi: 10.1016/j.neuropharm.2017.09.023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

¹Sobell Department of Motor Neuroscience, UCL Institute of Neurology & The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG

Corresponding author:

Professor Thomas Foltynie, Sobell Department of Motor Neuroscience, UCL Institute of Neurology & The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG

Email address: T.Foltynie@ucl.ac.uk

Telephone: +44 203 448 8726, Fax: +44 203 448 8642

Abstract

There is increasing interest in the potential role of glucagon-like peptide-1 (GLP-1) receptor agonists as neuroprotective treatments in neurodegenerative diseases including Parkinson's disease following the publication of the results of the Exenatide-PD trial. Of the current GLP-1 receptor agonists already licensed to treat Type 2 diabetes several including exenatide, liraglutide and lixisenatide are the subject of ongoing clinical trials in PD. The underlying rationale for using drugs licensed and effective for T2DM in PD patients therefore needs to be scrutinized, and the results obtained to date critically reviewed. We review the relationship between insulin resistance and Parkinson's disease, the implications on pathogenesis and the efforts to reposition GLP-1 agonists as potential treatments for Parkinson's disease and give an overview of the pre-clinical and clinical data supporting the use of exenatide in Parkinson's disease with a discussion regarding possible mechanisms of action.

Download English Version:

<https://daneshyari.com/en/article/8516567>

Download Persian Version:

<https://daneshyari.com/article/8516567>

[Daneshyari.com](https://daneshyari.com)